Background. Systemic antifungal medications can be lifesaving but can also have important toxicities. With a number of new antifungal drugs being introduced, there is a compelling need to define the toxicities associated with existing therapies.
significant incidence of toxic adverse effects. Fungal organisms are difficult to isolate in culture specimens [6] [7] [8] , so treatment with these drugs is often empirical.
Defining the toxicity of antifungal medications can be complicated by the severity of the patient's illness and by the difficulty in separating the effects of medication from the progress of fungal infection or of the underlying disease being treated. Elevation of liver function test values has been observed in multiple trials that have compared fluconazole with placebo [9] [10] [11] ; one trial found an increased rate of severe hepatic failure among fluconazole-treated patients, although this finding did not reach statistical significance [9] . Liver function abnormalities have also been noted with itraconazole treatment [12] . Trials comparing fluconazole with amphotericin B deoxycholate found hepatotoxicity in 10%-20% of all patients, without a significant difference between drugs [13, 14] . Studies of lipid-associated amphotericin B have reported elevated liver function test values in 15%-25% of treated patients [15, 16] .
Adverse event data collected in clinical trials can have important limitations. Patients in trials are carefully selected and may not have the same risk of complications as that of patients treated in routine hospital practice. Similarly, the clinical decision making that determines initiation of antifungal medications in routine practice may not parallel the processes and protocols used in clinical trials. Duration and dosing in a trial are predetermined, whereas dosing in typical situations may vary considerably. Examination of medication complications as they develop in routine practice settings can therefore play an important role in detecting adverse events that may not have been apparent in clinical trials.
Patients who undergo bone marrow transplantation are often given antifungal medications for proven fungal infections or as empirical treatment for fever in the presence of neutropenia. We sought to determine the association between exposure to antifungal medications and development of hepatotoxicity in routine practice in a large population of bone marrow transplant recipients.
METHODS

Study patients. Study patients were inpatients at Brigham and
Women's Hospital (Boston, MA) and Massachusetts General Hospital (Boston); both are large tertiary care hospitals affiliated with the Dana-Farber Cancer Institute. Patients were eligible for inclusion if they were admitted during the period of 1 January 2000 through 31 December 2001 and had a primary procedure of bone marrow transplantation. Only the initial admission for bone marrow transplantation was considered; readmissions for complications of previously performed transplantations were excluded. Institutional review board approval was obtained for the review of medical records.
Data sources. Data were obtained from several sources. The 2 hospitals maintain a common computerized data repository, which includes patients' demographic characteristics, diagnosis and procedure codes for hospital admissions, admission and discharge dates, discharge summaries, medications ordered, and laboratory results. This source was used to identify all patients admitted for bone marrow transplantation during the study period, as defined by the principal procedure code. This was confirmed by review of discharge summaries. Additional data from bone marrow transplantation databases maintained by the oncology divisions at each hospital were used to confirm diagnoses and to assign exact dates to certain events, such as the engraftment of transplanted cells or the development of complications.
Because use of antifungal medications was the principal interest, we reviewed the primary hospital record of each study patient to determine the exact doses and dates of use for all systemic antifungals (given orally or intravenously). We excluded medications used topically, including topical oral use that did not include swallowing (i.e., "swish and spit"). For other medications, the computerized data repository was used to determine the start date of treatment and the total amount of medication dispensed. Case definition and selection of control subjects. Case patients were patients who developed hepatotoxicity during their hospitalization, as defined by elevation of serum transaminase levels (aspartate aminotransferase [AST] or alanine aminotransferase [ALT]). Measurements of serum alkaline phosphatase and serum bilirubin levels were not included in the definition, because these laboratory test values are frequently abnormal in patients with cancer and patients undergoing bone marrow transplantations. For patients who were admitted with normal liver function test findings, an increase in either transaminase level to 13 times the upper limit of the normal range was used for the case definition. For patients admitted with abnormal transaminase levels (defined as 150% greater than the upper limit of normal), a doubling of the admission transaminase level was used for the case definition. The first date on which a patient had a serum transaminase level at or greater than the case-defining level was assigned as the index date.
We initially calculated crude incidence rates for the development of hepatotoxicity in patients in the cohort who were exposed to antifungal medications, before acquiring the status of case patients. Given the almost certain presence of confounding by indication, with more seriously ill patients being both more likely to receive antifungal medications and more likely to develop the outcome, we performed a case-control analysis to more accurately estimate the odds of hepatotoxicity with exposure to antifungal medications. To correct properly for possible confounding by indication, control subjects were drawn from a population of patients with a similar risk of having both drug exposure and the outcome of interest [17] . Thus, all patients in the cohort were eligible to be control subjects, including those who later became case patients. For each case patient, the time between date of hospital admission and index date was defined. A patient was randomly selected from the population as a potential control subject and was assigned an index date that would produce the same time at risk as the matching case patient. If a patient had been discharged or had become a case patient before the assigned index date, the patient was not used as a control subject; otherwise, the patient was assigned to the control group. Patients could serve as control subjects more than once. Up to 3 control subjects were selected per case patient.
Statistical analysis.
We used logistic regression to analyze the association between the development of hepatotoxicity and exposure to antifungal medications. Potential covariates included race, age, sex, disease for which transplantation was performed, type of transplantation (autologous vs. allogeneic), induction regimen, development of graft-versus-host disease, exposure to cyclosporine or tacrolimus, duration of neutropenia, use of total parenteral nutrition, and baseline transaminase level. Selection of potential clinical covariates for inclusion in the multivariate model was initially based on the univariate association between each variable and case status. Variables with a P value р.3 in univariate analyses were selected for possible inclusion. Initial analyses examined the association with antifungal medications, as measured by a simple indicator variable for exposure; additional analyses incorporated the total dose of antifungal medication, the maximum daily dose, and the time between initiation of antifungal therapy and the index date. ORs and 95% CIs were calculated for all analyses.
Follow-up analysis of case patients. Additional follow-up data were collected for the cohort of patients who developed hepatotoxicity, including whether antifungal therapy was continued or stopped, subsequent trends in transaminase levels, and trends in bilirubin levels. Additional analyses explored the association between the continued use of antifungal medication and the worsening of hepatotoxicity.
RESULTS
A total of 587 patients were admitted for bone marrow transplantation during the 2 study years. We identified 123 patients with hepatotoxicity in the total cohort, as well as 327 matched control subjects. Hospital charts could not be located for 4 case patients and 8 control subjects. After excluding these patients, there were 119 case patients and 319 control subjects, for an average of 2.7 control subjects per case patient. The mean time at risk was 15 days from hospital admission to index date. Table 1 shows the characteristics of the study population. Patients who developed hepatotoxicity did not differ from control subjects by sex or race, although case patients were somewhat younger than their matched control subjects (mean age, 43.2 vs. 46.9 years;
). Differences in the frequency of P ! .05 acute leukemia or myelodysplastic syndrome, chronic leukemia, or lymphoma were not statistically significant; these diagnoses accounted for ∼80% of diagnoses among both case patients and control subjects. However, of the remaining 20% of patients, control subjects were significantly more likely to have multiple myeloma, whereas case patients were more likely to have other diagnoses, including various solid tumors, aplastic anemia, and other conditions. The rate of allogeneic bone marrow transplantation was slightly over 60% in both cases and controls. Most induction regimens included cyclophosphamide; some regimens also included carmustine and etoposide. Use of these agents did not differ significantly between case patients and control subjects. Melphalan was used significantly more often by control subjects than by case patients; these treatment regimens were all administered for induction in patients with multiple myeloma. Case patients were exposed to cyclosporine or tacrolimus more often than were control subjects and developed acute graft-versus-host disease more often than did control subjects, although neither of these differences was statistically significant.
Exposures to antifungal medications are summarized in table 2. Fluconazole was used most commonly; a total of 125 patients were exposed to it. Amphotericin B deoxycholate was used by 40 patients, and liposomal amphotericin B was used by 52. Some patients received 11 antifungal medication, usually sequentially. Common combinations of agents were amphotericin B deoxycholate plus liposomal amphotericin B (15 patients) and amphotericin B deoxycholate plus fluconazole (10 patients). Itraconazole was used very infrequently (1 case patient We next developed multivariate models to measure the relationship between use of antifungals and development of hepatotoxicity. Univariate analyses found an association ( ) P р .3 for several variables (age, sex, race, diagnosis, exposure to immunosuppressive drugs [cyclosporine or tacrolimus], and development of graft-versus-host disease). These variables were included in the multivariate models. Other factors, such as induction regimen, type of bone marrow transplantation, and duration of neutropenia, yielded a P value of 1.3 on univariate analysis and were not included in the multivariate model.
An association between parenteral nutrition and hepatotoxicity has been established, although it is unclear whether the lipid or the carbohydrate component is more important in this association [18] [19] [20] [21] . To explore this association, we recorded the total amount of lipids, amino acids, and dextrose infused during parenteral nutrition. There was a trend toward increased risk of hepatotoxicity with increasing total exposure to each of these components, although the association was not statistically significant. The trend was strongest and most consistent for the total amount of amino acid infused and met the prespecified threshold of in univariate analyses, so we included this P р .3 exposure in the final model.
In patients who were exposed to a single antifungal agent, significant associations with hepatotoxicity were seen for liposomal amphotericin B (OR, 3.78; 95% CI, 1.42-10.0) and fluconazole (OR, 2.57; 95% CI, 1.47-4.52). Although amphotericin B deoxycholate exposure was associated with an OR of 2.01, its 95% CI (0.40-10.2) was very wide (table 3) . A combined analysis of all patients exposed to only 1 antifungal medication yielded similar ORs. In the entire population, including patients who received 11 agent, the ORs for liposomal amphotericin B (3.33; 95% CI, 1.61-6.88) and fluconazole (1.99; 95% CI, 1.21-3.26) were similar to those in the single-exposure models.
We next examined whether the total dose or duration of antifungal treatment was associated with the development of hepatotoxicity, and we found that an increase in liver function test value was associated with increasing exposure to liposomal amphotericin B; no consistent dose-response relationship was seen for amphotericin B deoxycholate or fluconazole (figure 1). The trend was most marked when the maximum daily dose of liposomal amphotericin B was considered, although similar relationships were observed for the duration of therapy and the total amount of medication received (in milligrams). Of note, the mean duration of therapy before the index date was shorter for patients exposed to amphotericin B deoxycholate than for those exposed to liposomal amphotericin B or fluconazole. We also calculated rates of incident hepatotoxicity from cohort and follow-up perspectives for these patients. The crude rate of new hepatotoxicity was 0.78 cases per 100 patient-days of exposure to amphotericin B deoxycholate, 0.98 cases per 100 patient-days for exposure to fluconazole, and 1.50 cases per 100 patient-days for exposure to liposomal amphotericin B. Table 4 presents follow-up data for the patients who met criteria for hepatic abnormalities and who continued to receive antifungals. Among 23 patients treated with liposomal amphotericin B, 19 continued to receive therapy after the initial elevation in the transaminase levels. Nearly one-half of these patients had either decreases or minimal additional increases in transaminase levels, one-third had moderate continued increases to approximately double the values from the index date, and the remaining 5 patients had larger increases (up to у10 times the upper limit of normal). The mean maximum ALT level for these 5 patients was 1600 U/L (range, 599-3936 U/L). Of these same patients, the bilirubin level remained stable or increased moderately in two-thirds, whereas one-third had bilirubin levels that exceeded 10 mg/dL with continued treatment (mean, 23.9 mg/dL; range, 11.5-42.7 mg/dL). All of these patients had undergone allogeneic transplantations for acute leukemia, and all died. All 4 patients who stopped receiving liposomal amphotericin B subsequently had stable transaminase levels; 1 of the 4 had a slight increase in the bilirubin level to twice the upper limit of normal, and the other 3 had stable bilirubin levels after they ceased to receive this drug. By contrast, all but 1 of the 14 patients treated with amphotericin B deoxycholate stopped treatment on or before the date of onset of hepatotoxicity.
Of the patients who were treated with fluconazole, 25 continued to receive treatment after the onset of hepatotoxicity. More than one-half had stable or decreasing transaminase levels, but sharp increases in transaminase levels (to у10 times the upper limit of normal) occurred in 12% of these patients (mean ALT level, 879 U/L; range, 731-974 U/L). Only 2 of these patients had increases in bilirubin levels to у10 mg/dL (11.1 and 14.8 mg/dL).
DISCUSSION
We studied risk factors for the development of hepatotoxicity, as measured by elevations of the serum transaminase levels, in a population of bone marrow transplant recipients. We found a substantial increase in the risk of this outcome after receipt of liposomal amphotericin B, which was considerably greater than the increase seen for fluconazole or amphotericin B deoxycholate.
Although some prior work has noted changes in liver function associated with amphotericin B exposure, these changes are not as well established as the changes associated with azole agents. In a comparison of amphotericin B deoxycholate and fluconazole, hyperbilirubinemia was more common among patients treated with amphotericin B deoxycholate [14] . An openlabel trial of patients treated with amphotericin B lipid complex found that AST levels doubled after treatment [16] .
Prior research has yielded inconsistent results for the association between use of other antifungal agents and hepatic dysfunction. Although some investigators have not found a clear association between fluconazole use and hepatic damage [9, 15, 22] , other studies have found increased transaminase levels among patients with leukemia and among patients undergoing bone marrow transplantation [10, 11] . Isolated instances of hepatic failure with fluconazole therapy have also been reported [23, 24] . We also found an association between fluconazole use and hepatotoxicity, although we did not observe consistent dose-response relationships between fluconazole exposure and the extent of abnormal liver function test values. Although hepatotoxicity has been reported with itraconazole use [12] , we had too few exposures to include that agent in our analyses. Hepatotoxicity rates of 5%-15% have been reported for voriconazole [25] , but this medication was not available during our study period.
The mechanism of the association between liposomal amphotericin B and hepatotoxicity is unclear. The lack of increased risk with conventional amphotericin B in our analyses suggests that it may involve the lipid component of the preparation. Several new antifungal agents have been introduced in recent years, and additional agents are either in clinical trials or being reviewed by the US Food and Drug Administration. Concerns have already been raised about the potential hepatotoxicity of voriconazole [25] [26] [27] , one of the recently approved new medications. Understanding the risks of the older antifungal medications will help put these risks into context and assist clinicians in comparing the risks and benefits of drugs in this class.
We defined an elevation of transaminase levels to 13 times the upper limit of normal as the outcome of interest. With use of this definition, the crude incidence of hepatotoxicity was highest in patients exposed to liposomal amphotericin B. In addition, we found trends suggesting an association between higher doses of liposomal amphotericin B and more marked abnormal liver function findings. Among patients who continued to receive liposomal amphotericin B after the onset of hepatotoxicity, 32% developed marked elevations in the bilirubin level; this was usually apparent in the first 2-3 days of continued therapy. By contrast, only 2 (8%) of 25 patients who continued to receive fluconazole developed elevated bilirubin levels that required stopping the treatment.
These findings suggest that many patients who develop elevated transaminase levels while being treated with these agents can continue to receive treatment with careful monitoring, particularly for fluconazole therapy. Whether this observation extends to other azole antifungals is an important area for future research. We cannot draw any conclusions about continuation of amphotericin B deoxycholate therapy, given that almost no patients continued to receive treatment with that agent after developing hepatotoxicity. Our primary analyses were similarly limited with regard to amphotericin B deoxycholate because of the relatively low number of exposed patients and short duration of exposure; this was reflected in the wide 95% CIs around the OR for amphotericin B deoxycholate.
These results must be viewed in light of several important limitations. Our primary analyses are based on a retrospective case-control study, which adjusted for all available clinical variables that might have explained changes in hepatic function. Nevertheless, unmeasured patient factors might have influenced both the clinical decision of which antifungal medication to use and the development of hepatotoxicity, thereby confounding the analysis. For example, physicians may have chosen to administer liposomal amphotericin B to patients with a poorer prognosis and a higher risk of hepatotoxicity and thus biased the results. We did not extract data from physician progress notes. However, the higher ORs found for liposomal amphotericin B persisted after adjustment for a wide variety of baseline characteristics. Both hospitals used the same form of liposomal amphotericin B (AmBisome; Fujisawa Healthcare), so we cannot know whether these findings would apply to other lipid preparations of amphotericin B.
In summary, this case-control analysis of a population of bone marrow transplant recipients demonstrates an association between the administration of liposomal amphotericin B and hepatotoxicity. This observation does not, in itself, prove causality, and a better understanding of the mechanism of this association is an important aim for future research. As more patients develop fungal infection while taking long-term immunosuppressing agents and as multiple new antifungal medications become available, surveillance for hepatotoxicity and other adverse events in this setting represents an important clinical priority.
